Aspergillus: A Deadly Superfungus on the Rise – Part 1
In 2018, three children developed invasive aspergillosis—a severe, aggressive fungal infection—after undergoing surgery at Seattle Children’s Hospital, a top U.S. medical center. Hospital authorities traced the source to airborne Aspergillus mold spores in selected operating suites, exhaustively cleaned the spaces, and sealed potential air leaks. Follow-up air quality testing returned negative for additional traces of the fungus.
“We believed that the work we had done to those rooms had solved the problem,” a hospital official announced.
They were mistaken.
A year later, three more pediatric patients developed invasive Aspergillus infections, resulting in one fatality. The facility subsequently closed 14 operating rooms and postponed over 1,000 surgical procedures while crews overhauled the compromised air filtration systems that had dispersed the lethal fungal spores.
The Rising Threat of Hospital-Acquired Fungal Pathogens
While airborne bacteria and viruses dominate infection control headlines, fungal pathogens pose a severe hazard to immunocompromised patients. Among the most dangerous is Aspergillus, an environmental mold naturally present in soil and frequently launched airborne during nearby hospital construction or renovation.
“This disease remains difficult to diagnose and treat, and case fatality remains high,” cautions a national health report on invasive aspergillosis prevention.
Invasive aspergillosis accounts for up to 40% of all hospital-acquired fungal infections. According to data cited by the U.K. National Health Service, global estimates of 300,000 annual invasive cases are almost certainly a significant underestimate.
In recent years, aspergillosis has emerged as a broader clinical risk. The disease is striking patient populations previously considered at low risk, while the pool of highly vulnerable patients continues to expand alongside medical advancements that preserve life through intensive immunosuppression.
Antifungal Resistance and Diagnostic Challenges
Compounding the problem is the emergence of drug-resistant Aspergillus strains—often referred to as a "superfungus"—that exhibit resistance to front-line triazole antifungal medications. Resistant strains, widespread in Europe, have been documented globally, complicating treatment for a disease that carries up to a 50% overall mortality rate.
For high-risk immunocompromised individuals, even minimal exposure—fewer than 1 colony-forming unit (CFU)/m³ of air—can initiate systemic infection. However, clinical diagnosis is frequently delayed because initial symptoms (fever, chills, shortness of breath, joint pain, and headaches) mimic common respiratory infections.
To protect vulnerable patient populations, healthcare facilities must combine rigorous dust control during renovations with continuous, medical-grade air disinfection to eliminate microscopic spores from patient care environments.
High-Risk Patient Populations
Approximately 40 species of Aspergillus can cause human infection, led by Aspergillus fumigatus, A. flavus, A. niger, and A. terreus. In healthy individuals, innate immune defenses easily neutralize inhaled spores. However, microscopic spores measuring just 2 to 3 micrometers in diameter easily reach deep pulmonary alveoli.
In severely immunocompromised hosts, the fungus can cross the alveolar-capillary barrier into the bloodstream, metastasizing to the brain, heart, kidneys, skin, or eyes. Historically, the most vulnerable groups included:
- Hematologic malignancy patients receiving intensive chemotherapy
- Hematopoietic stem cell transplant (HSCT) recipients
- Solid organ transplant recipients (particularly lung and heart transplants)
In a systematic review of 53 hospital aspergillosis outbreaks, 65% of affected patients had an underlying blood cancer.
However, recent epidemiological studies highlight an expanding risk profile beyond traditional oncology wards. Vulnerable populations now include premature infants, patients with chronic obstructive pulmonary disease (COPD), severe burns, uncontrolled diabetes, liver cirrhosis, and patients suffering from acute viral pneumonias.
A high proportion of invasive cases are diagnosed in intensive care units among non-neutropenic patients with severe viral infections, including influenza and hospital-acquired pneumonia. For instance, observational studies in European ICUs revealed that up to 22% of critically ill influenza patients developed secondary invasive pulmonary aspergillosis shortly after admission.